Morgan Stanley analyst Michael Ulz downgraded Iveric bio (ISEE) to Equal Weight from Overweight with a price target of $40, up from $35, after Astellas Pharma (ALPMY) agreed to acquire Iveric for $40 per share in cash. The firm, which views the deal as "a positive," continues to expect approval of avacincaptad pegol for geographic atrophy, or GA, in Q3, noting that it has a PDUFA date of August 19.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ISEE: